Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 2Colorectal Neoplasms 2Vulvar Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Melanoma 1Locally Advanced Rectal Carcinoma 1Hypoxia 1Gliosarcoma 1Glioma 1Genetic Diseases, Inborn 1Esophageal Neoplasms 1Circulating Tumor DNA 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 58Cisplatin 41Capecitabine 27Oxaliplatin 25durvalumab 16Fluorouracil 16Leucovorin 15S 1 (combination) 11lenvatinib 10Nivolumab 10Irinotecan 10pembrolizumab 8apatinib 8Immune Checkpoint Inhibitors 7130-nm albumin-bound paclitaxel 7tremelimumab 6Bevacizumab 6camrelizumab 5Trastuzumab 5Drug Therapy 5Blood Specimen Collection 5Albumin-Bound Paclitaxel 5tislelizumab 4irinotecan sucrosofate 4Taxes 4Liquid Biopsy 4Folfox protocol 4toripalimab 3surufatinib 3gemcitabine-oxaliplatin regimen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Neoplasms × Circulating Tumor DNA × Clear all
NCT07142226 2026-03-18

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

CHA University

Recruiting
200 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡